Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2023)

Recursion Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $11.1 million for Q3 2023.

• Quarterly Receivables fell 4.91% year-over-year to $11.1 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $11.1 million (down 4.91% YoY) and the FY2022 annual result came in at $2.8 million, down 69.71% from the prior year.
• Receivables was $11.1 million for Q3 2023 at Recursion Pharmaceuticals, up from $10.2 million in the prior quarter.
• Across five years, Receivables topped out at $11.7 million in Q2 2022 and bottomed at $49000.0 in Q2 2021.
• A 4-year average of $6.4 million and a median of $9.1 million in 2021 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 23736.73% in 2022, while the deepest fall reached 69.71% in 2022.
• Recursion Pharmaceuticals' Receivables stood at $156000.0 in 2020, then surged by 5726.92% to $9.1 million in 2021, then tumbled by 69.71% to $2.8 million in 2022, then surged by 301.89% to $11.1 million in 2023.
• Business Quant data shows RXRX's Receivables at $11.1 million in Q3 2023, $10.2 million in Q2 2023, and $2.8 million in Q4 2022.